Company Profile
Synlogic Stock Price, News & Catalysts
- Ticker:
- SYBX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.16 USD (0.00%)
Close
Last updated: September 17, 2026
—
Market cap
Why the stock is moving
As of Sep 17, 2026, SYBX was little changed and closed at $1.16. No new same-company headline was identified in the current news window.
Company overview
Business overview
Synlogic was a synthetic-biology company focused on engineered microbes and metabolic disease before its restructuring and decline. Its platform aimed to use living medicines to address rare disorders.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ before restructuring, Synlogic sat in synthetic biology and biotechnology.
Business Model Characteristics
The company depended on platform validation, clinical proof, and the ability to turn engineered-microbe science into value.
Position Within the Biotechnology Landscape
Synlogic belongs to the historical synthetic-biology category rather than the current live public-company set.
Future catalysts
- Synlogic is now mostly a legacy and closeout story, so the catalysts are any strategic or asset-resolution update rather than a live pipeline milestone. The market is mainly waiting for clarity on what value, if any, remains.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Synlogic (SYBX)?
Synlogic (SYBX) most recently closed at 1.16 USD, a 0.00% move versus the previous session.
What does Synlogic do?
Synlogic was a synthetic-biology company focused on engineered microbes and metabolic disease before its restructuring and decline. Its platform aimed to use living medicines to address rare disorders.
On which exchange is SYBX stock listed?
Synlogic (SYBX) is associated with NASDAQ, United States, Biopharma.
What is Synlogic?
Synlogic is now mostly a legacy and closeout story, so the catalysts are any strategic or asset-resolution update rather than a live pipeline milestone.
Which conditions is Synlogic targeting with Synlogic?
Synlogic is associated with metabolic disease based on its company overview and current catalyst commentary.
How does Synlogic describe recent progress with Synlogic?
Synlogic is now mostly a legacy and closeout story, so the catalysts are any strategic or asset-resolution update rather than a live pipeline milestone.
What future catalysts are investors watching for Synlogic?
Synlogic is now mostly a legacy and closeout story, so the catalysts are any strategic or asset-resolution update rather than a live pipeline milestone. The market is mainly waiting for clarity on what value, if any, remains.